Concomitant heterochromatinisation and down-regulation of gene expression unveils epigenetic silencing of RELB in an aggressive subset of chronic lymphocytic leukemia in males

详细信息    查看全文

• 作者：Jean-Brice Marteau (1)
  Odile Rigaud (1)
  Thibaut Brugat (1) (5) (6)
  Nathalie Gault (1)
  Laurent Vallat (2)
  Mogens Kruhoffer (3)
  Torben F Orntoft (3)
  Florence Nguyen-Khac (2)
  Sylvie Chevillard (4)
  Hélène Merle-Beral (2)
  Jozo Delic (1) (4)
  
• 刊名：BMC Medical Genomics
• 出版年：2010
• 出版时间：December 2010
• 年：2010
• 卷：3
• 期：1
• 全文大小：3279KB
• 参考文献：1. Mauro FR, De RG, Burgio VL, Caruso R, Giannarelli D, Monarca B, Romani C, Baroni CD, Mandelli F: Prognostic value of bone marrow histology in chronic lymphocytic leukemia. A study of 335 untreated cases from a single institution. / Haematologica 1994, 79: 334-41.
  2. Mauro FR, Foa R, Giannarelli D, Cordone I, Crescenzi S, Pescarmona E, Sala R, Cerretti R, Mandelli F: Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. / Blood 1999, 94: 448-54.
  3. Cartwright RA, Gurney KA, Moorman AV: Sex ratios and the risks of haematological malignancies. / Br J Haematol 2002, 118: 1071-077. CrossRef
  4. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. / Blood 1999, 94: 1840-847.
  5. Haslinger C, Schweifer N, Stilgenbauer S, D?hner H, Lichter P, Kraut N, Stratowa C, Abseher R: Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. / J Clin Oncol 2004, 22: 3937-949. CrossRef
  6. Rosenwald A, Chuang EY, Davis RE, Wiestner A, Alizadeh AA, Arthur DC, Mitchell JB, Marti GE, Fowler DH, Wilson WH, Staudt LM: Fludarabine treatment of patients with chronic lymphocytic leukemia induces p53-dependent gene expression response. / Blood 2004, 104: 1428-434. CrossRef
  7. Vallat L, Magdelénat H, Merle-Béral H, Masdehors P, Potocki de Montalk G, Davi F, Kruhoffer M, Sabatier L, Orntoft TF, Delic J: The resistance of CLL cells to DNA damage-induced apoptosis defined by DNA microarrays. / Blood 2003, 101: 4598-606. CrossRef
  8. Stratowa C, L?ffler G, Lichter P, Stilgenbauer S, Haberl P, Schweifer N, D?hner H, Wilgenbus KK: cDNA microarray gene expression analysis of B-cell chronic lymphocytic leukemia proposes potential new prognostic markers involved in lymphocyte trafficking. / Int J Cancer 2001, 91: 474-80. CrossRef
  9. Klein U, Tu Y, Stolovitzky GA, Mattioli M, Cattoretti G, Husson H, Freedman A, Inghirami G, Cro L, Baldini L, Neri A, Califano A, Dalla-Favera R: Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. / J Exp Med 2001, 194: 1625-638. CrossRef
  10. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, Yang L, Pickeral OK, Rassenti LZ, Powell J, Botstein D, Byrd JC, Grever MR, Cheson BD, Chiorazzi N, Wilson WH, Kipps TJ, Brown PO, Staudt LM: Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. / J Exp Med 2001, 194: 1639-647. CrossRef
  11. Durig J, Nückel H, Hüttmann A, Kruse E, H?lter T, Halfmeyer K, Führer A, Rudolph R, Kalhori N, Nusch A, Deaglio S, Malavasi F, M?r?y T, Klein-Hitpass L, Dührsen U: Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. / Blood 2003, 101: 2748-755. CrossRef
  12. Wahlfors J, Hiltunen H, Heinonen K, H?m?l?inen E, Alhonen L, J?nne J: Genomic hypomethylation in human chronic lymphocytic leukemia. / Blood 1992, 80: 2074-080.
  13. Plass C, Byrd JC, Raval A, Tanner SM, de la Chapelle A: Molecular profiling of chronic lymphocytic leukaemia: genetics meets epigenetics to identify predisposing genes. / Br J Haematol 2007, 139: 744-52. CrossRef
  14. Dunn BK: Hypomethylation: one side of a larger picture. / Ann N Y Acad Sci 2003, 983: 28-2. CrossRef
  15. Bitoun E, Oliver PL, Davies KE: The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling. / Hum Mol Genet 2007, 16: 92-06. CrossRef
  16. Ting AH, McGarvey KM, Baylin SB: The cancer epigenome--components and functional correlates. / Genes Dev 2006, 20: 3215-231. CrossRef
  17. Raval A, Tanner SM, Byrd JC, Angerman EB, Perko JD, Chen SS, Hackanson B, Grever MR, Lucas DM, Matkovic JJ, Lin TS, Kipps TJ, Murray F, Weisenburger D, Sanger W, Lynch J, Watson P, Jansen M, Yoshinaga Y, Rosenquist R, de Jong PJ, Coggill P, Beck S, Lynch H, de la Chapelle A, Plass C: Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. / Cell 2007, 129: 879-90. CrossRef
  18. Qin LX, Beyer RP, Hudson FN, Linford NJ, Morris DE, Kerr KF: Evaluation of methods for oligonucleotide array data via quantitative real-time PCR. / BMC Bioinformatics 2006, 7: 23. CrossRef
  19. Dupuy A, Simon R: Critical review of published microarray studies for cancer outcome guidelines on statistical analysis and reporting. / J Natl Cancer Inst 2007, 99: 147-57. CrossRef
  20. Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to ionizing radiation response. / Proc Natl Acad Sci USA 2001, 98: 5116-121. CrossRef
  21. Ancelin K, Brunori M, Bauwens S, Koering CE, Brun C, Ricoul M, Pommier JP, Sabatier L, Gilson E: Targeting assay to study the cis functions of human telomeric proteins: evidence for inhibition of telomerase by TRF1 and for activation of telomere degradation by TRF2. / Mol Cell Biol 2002, 22: 3474-487. CrossRef
  22. Deriano L, Guipaud O, Merle-Béral H, Binet JL, Ricoul M, Potocki-Veronese G, Favaudon V, Maciorowski Z, Muller C, Salles B, Sabatier L, Delic J: Human chronic lymphocytic leukemia B cells can escape DNA damage-induced apoptosis through the nonhomologous end-joining DNA repair pathway. / Blood 2005, 105: 4776-783. CrossRef
  23. Lee TI, Johnstone SE, Young RA: Chromatin immunoprecipitation and microarray-based analysis of protein location. / Nat Protoc 2006, 1: 729-48. CrossRef
  24. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. / Nature 2000, 403: 503-11. CrossRef
  25. Praz F, Le Page F, Vallat L, Davi F, Nguyen-Khac F, Maloum K, Delic J, Merle-Béral H: Absence of microsatellite instability in human chronic lymphocytic leukaemia B cells. / Leukemia 2008, 22: 186-89. CrossRef
  26. Otake Y, Soundararajan S, Sengupta TK, Kio EA, Smith JC, Pineda-Roman M, Stuart RK, Spicer EK, Fernandes DJ: Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA. / Blood 2007, 109: 3069-075.
  27. Roos G, Kr?ber A, Grabowski P, Kienle D, Bühler A, D?hner H, Rosenquist R, Stilgenbauer S: Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. / Blood 2008, 111: 2246-252. CrossRef
  28. Peng JC, Karpen GH: H3K9 methylation and RNA interference regulate nucleolar organization and repeated DNA stability. / Nat Cell Biol 2007, 9: 25-5. CrossRef
  29. Blasco MA: The epigenetic regulation of mammalian telomeres. / Nat Rev Genet 2007, 8: 299-09. CrossRef
  30. Sasaki H, Jones PA, Chaillet JR, Ferguson-Smith AC, Barton SC, Reik W, Surani MA: Parental imprinting: potentially active chromatin of the repressed maternal allele of the mouse insulin-like growth factor II (Igf2) gene. / Genes Dev 1992, 6: 1843-856. CrossRef
  31. Wu J, Wang SH, Potter D, Liu JC, Smith LT, Wu YZ, Huang TH, Plass C: Diverse histone modifications on histone 3 lysine 9 and their relation to DNA methylation in specifying gene silencing. / BMC Genomics 2007, 7: 131. CrossRef
  32. Brugat T, Gault N, Baccelli I, Ma?s J, Roborel de Climens A, Nguyen-Khac F, Davi F, Merle-Béral H, Gilson E, Goodhardt M, Delic J: Aberrant telomere structure is characteristic of resistant chronic lymphocytic leukaemia cells. / Leukemia 2010, 24: 246-51. CrossRef
  33. Brugat T, Nguyen-Khac F, Merle-Beral H, Delic J: Telomere dysfunction-induced foci arise with the onset of telomeric deletions and complex chromosomal aberrations in resistant chronic lymphocytic leukemia cells. / Blood 2010, 113: 239-49. CrossRef
  34. Hayden MS, Ghosh S: Shared principles in NF-kappaB signaling. / Cell 2008, 132: 344-62. CrossRef
  35. Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML, Jordan CT, Neelakantan S, Crooks PA, Burnett AK, Pratt G, Fegan C, Rowntree C, Brennan P, Pepper C: The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. / Blood 2008, 111: 4681-689. CrossRef
  36. Mills DM, Bonizzi G, Karin M, Rickert RC: Regulation of late B cell differentiation by intrinsic IKKalpha-dependent signals. / Proc Natl Acad Sci USA 2007, 104: 6359-364. CrossRef
  37. Goldmit M, Ji Y, Skok J, Roldan E, Jung S, Cedar H, Bergman Y: Epigenetic ontogeny of the Igk locus during B cell development. / Nat Immunol 2005, 6: 198-03. CrossRef
  38. Das C, Gadad SS, Kundu TK: Human positive coactivator 4 controls heterochromatinization and silencing of neural gene expression by interacting with REST/NRSF and CoREST. / J Mol Biol 2010, 397: 1-2. CrossRef
  39. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1755-8794/3/53/prepub
  
• 作者单位：Jean-Brice Marteau (1)
  Odile Rigaud (1)
  Thibaut Brugat (1) (5) (6)
  Nathalie Gault (1)
  Laurent Vallat (2)
  Mogens Kruhoffer (3)
  Torben F Orntoft (3)
  Florence Nguyen-Khac (2)
  Sylvie Chevillard (4)
  Hélène Merle-Beral (2)
  Jozo Delic (1) (4)
  
  1. Laboratoire d’Onco-Hématologie (LOH), Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA) Direction des Sciences du Vivant (DSV) Institut de Radiobiologie Cellulaire et Moléculaire (IRCM), France
  5. Université René Descartes-Paris V, 4, Av de l'Observatoire, 75006, Paris, France
  6. Jean Langhorne's Lab, Division of Parasitology, National Institute for Medical Research, NW71AA, The Ridgeway London, UK
  2. é Salpêtrière, Service d’Hématologie Biologique, AP-HP, Université Paris 6, Inserm U543, 47, Bd de l’H?pital, 75013, Paris, France
  3. Department of Clinical Biochemistry, University of Aarhus, Brendstrupgaardsvej 100, DK-8200, Aarhus, Denmark
  4. Direction des Sciences du Vivant (DSV) Institut de Radiobiologie Cellulaire et Moléculaire (IRCM), Laboratoire de Cancérologie Expérimentale (LCE), Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), 18, Av du Panorama, 92265, Fontenay-aux-Roses, France
  
• ISSN：1755-8794

文摘

Background The sensitivity of chronic lymphocytic leukemia (CLL) cells to current treatments, both in vitro and in vivo, relies on their ability to activate apoptotic death. CLL cells resistant to DNA damage-induced apoptosis display deregulation of a specific set of genes. Methods Microarray hybridization (Human GeneChip, Affymetrix), immunofluorescent in situ labeling coupled with video-microscopy recording/analyses, chromatin-immunoprecipitation (ChIP), polymerase chain reactions (PCR), real-time quantitative PCR (RT-QPCR) and bisulfite genome sequencing were the main methods applied. Statistical analyses were performed by applying GCRMA and SAM analysis (microarray data) and Student's t-test or Mann & Whitney's U-test. Results Herein we show that, remarkably, in a resistant male CLL cells the vast majority of genes were down-regulated compared with sensitive cells, whereas this was not the case in cells derived from females. This gene down-regulation was found to be associated with an overall gain of heterochromatin as evidenced by immunofluorescent labeling of heterochromatin protein 1α (HP-1), trimethylated histone 3 lysine 9 (3metH3K9), and 5-methylcytidine (5metC). Notably, 17 genes were found to be commonly deregulated in resistant male and female cell samples. Among these, RELB was identified as a discriminatory candidate gene repressed in the male and upregulated in the female resistant cells. Conclusion The molecular defects in the silencing of RELB involve an increase in H3K9- but not CpG-island methylation in the promoter regions. Increase in acetyl-H3 in resistant female but not male CLL samples as well as a decrease of total cellular level of RelB after an inhibition of histone deacetylase (HDAC) by trichostatin A (TSA), further emphasize the role of epigenetic modifications which could discriminate two CLL subsets. Together, these results highlighted the epigenetic RELB silencing as a new marker of the progressive disease in males.